about Carole Nuechterlein, J.D.:

Dr. Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.

Carole currently serves as a director at CiVi Biopharma, Lumos Pharma, Lysosomal Therapeutics, Inc., Millendo Therapeutics, Mission Therapeutics, Second Genome, Tioma Therapeutics and Vivet Therapeutics and as board observer on Allakos, C4 and Maculogix.  Carole also led the investments on Alios, Ambit, AveXis, Conatus, Envoy & Pharmasset.

Dr. Nuechterlein has a BA from Valparaiso University and a JD from University of Michigan.